Literature DB >> 18304004

The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.

Ya-Lin Chiu1, Warner C Greene.   

Abstract

All retroviruses, including HIV-1, display species-specific patterns of infection. The impaired growth of these retroviruses in foreign and sometimes even in their natural hosts often stems from the action of potent host-encoded "viral restriction factors" that form important protective components of the innate immune system. The discovery of APOBEC3G and related cytidine deaminases as one class of host restriction factors and of the action of HIV-1 Vif as a specific APOBEC3G antagonist have stimulated intense scientific interest. This Vif-APOBEC3G axis now forms a very attractive target for development of an entirely new class of anti-HIV drugs. In this review, we summarize current understanding of the mechanism of action of the APOBEC3 family of enzymes, their intriguing regulation within cells, the impact of these enzymes on viral evolution and disease progression, and their roles in controlling not only the replication of exogenous retroviruses but also the retrotransposition of endogenous retroelements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18304004     DOI: 10.1146/annurev.immunol.26.021607.090350

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  249 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.

Authors:  Wenyan Zhang; Juan Du; Sean L Evans; Yunkai Yu; Xiao-Fang Yu
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

4.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

5.  Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution.

Authors:  Gayan Senavirathne; Malgorzata Jaszczur; Paul A Auerbach; Thomas G Upton; Linda Chelico; Myron F Goodman; David Rueda
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

6.  Suboptimal provirus expression explains apparent nonrandom cell coinfection with HIV-1.

Authors:  Christelle Brégnard; Gregory Pacini; Olivier Danos; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

7.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

8.  Epigenetic control of retrotransposon expression in human embryonic stem cells.

Authors:  Angela Macia; Martin Muñoz-Lopez; Jose Luis Cortes; Robert K Hastings; Santiago Morell; Gema Lucena-Aguilar; Juan Antonio Marchal; Richard M Badge; Jose Luis Garcia-Perez
Journal:  Mol Cell Biol       Date:  2010-11-01       Impact factor: 4.272

Review 9.  Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases.

Authors:  Elisa Orecchini; Loredana Frassinelli; Silvia Galardi; Silvia Anna Ciafrè; Alessandro Michienzi
Journal:  Chromosome Res       Date:  2018-02-02       Impact factor: 5.239

10.  Jun activation domain-binding protein 1 (JAB1) is required for the optimal response to interferons.

Authors:  Ryuta Muromoto; Maiko Nakajima; Koki Hirashima; Toru Hirao; Shigeyuki Kon; Kazuya Shimoda; Kenji Oritani; Tadashi Matsuda
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.